Le Lézard
Classified in: Health
Subject: SVY

Global Biomarkers Report 2018 - Technologies, Markets and Companies Estimates & Forecasts 2017-2027


DUBLIN, Feb. 23, 2018 /PRNewswire/ --

The "Biomarkers - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

This report follows the broad definition of a biomarker as a characteristic that can be objectively measured and evaluated as an indicator of normal biological or pathogenic processes as well as pharmacological responses to a therapeutic intervention. Tests based on biomarkers have been around for more than half a century, but interest in their application for diagnostics and drug discovery as well as development has increased remarkably since the beginning of the 21st century.

This report describes different types of biomarkers and their discovery using various -omics technologies such as proteomics and metabolomics. Molecular diagnostics technologies are used for the discovery of biomarkers and new tests are also based on biomarker.

Currently the most important applications of biomarkers are in drug discovery and development. The role of biomarkers in various therapeutic areas particularly cancer, cardiovascular diseases and disorders of the central nervous system, is described. Biomarkers are useful not only for diagnosis of some of these diseases but also for understanding the pathomechanism as well as a basis for development of therapeutics.

Biomarkers will facilitate the combination of therapeutics with diagnostics and will thus play an important role in the development of personalized medicine. Biomarkers play a role in use of pharmacogenetics, pharmacogenomics and pharmacoproteomics for development of personalized medicine.

Many of the regulatory issues concerning biomarkers are related to genomics, proteomics, molecular diagnostics and pharmacogenomics/pharmacogenetics. Validation of biomarkers and their role in clinical trials is discussed.

Biomarker markets are estimated from 2017 to 2027 according to share of markets for various technologies and applications: proteomics, metabolomics, molecular diagnostics, drug discovery, clinical trials, and bioinformatics. Market values are further split according to therapeutic applications and major geographical areas. Unfulfilled needs in biomarkers are identified as well as the drivers for biomarker markets. Challenges facing the biomarker industry and strategies for developing biomarker markets are discussed.

A large number of companies with varying technical backgrounds are involved in biomarkers and 302 of these are profiled in part 2 of the report with classification into various categories.These also include major pharmaceutical companies. There is tabulation of 466 collaborations between companies and additional academic collaborations are mentioned in the individual profiles of companies. The report is supplemented by 910 references, 80 tables and 23 figures

Key Topics Covered:

Part 1: Technologies & Applications

Executive Summary

1. Introduction

2. Technologies for Discovery of Biomarkers

3. Biomarkers and Molecular Diagnostics

4. Biomarkers for Drug Discovery & Development

5. Role of Biomarkers in Healthcare

6. Biomarkers in Metabolic Disorders

7. Biomarkers in Immune Disorders

8. Biomarkers of Musculoskeletal Disorders

9. Biomarkers of Infectious Diseases

10. Biomarkers of Genetic Disorders

11. Biomarkers of Aging

12. Nutritional Biomarkers

13. Biomarkers of Cancer

14. Biomarkers of Disorders of the Nervous System

15. Biomarkers of Cardiovascular Disorders

16. Biomarkers of Pulmonary Diseases

17. Biomarkers in Gynecology and Obstetrics

18. Biomarkers & Personalized Medicine

19. Biomarkers and Regulatory issues

20. References

Part II: Markets & Companies

21. Markets for Biomarkers

22. Companies

For more information about this report visit https://www.researchandmarkets.com/research/qq3r88/global_biomarkers?w=5

Media Contact:


Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 17:31
The rise in demand for dental lasers is mainly driven by the growing occurrence of dental issues like bleeding or inflamed gums, tooth decay, and root infections. Furthermore, advancements in dental technology play a significant role in fostering...

at 17:26
Amgen today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American...

at 17:05
Antibe Therapeutics Inc. ("Antibe" or the "Company") announced that the Toronto Stock Exchange ("TSX") is reviewing the eligibility for continued listing on the TSX of the securities of the Company. The TSX has identified the Company's financial...

at 16:30
Viatris Inc.  will report its first quarter 2024 financial results on Thursday, May 9, 2024, before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith and other Company executives will host a webcast at 8:30 a.m. ET on the...

at 16:30
WELL Health Clinic Network Inc. ("WELL"), a subsidiary of WELL Health Technologies Corp. , a digital healthcare company focused on...

at 16:25
Precision BioSciences, Inc. , an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company. Precision exercised its option to regain...



News published on and distributed by: